Matthew Rizzo Net Worth

The estimated Net Worth of Matthew Rizzo is at least $2.04 Million dollars as of 14 February 2018. Mr. Rizzo owns over 945,819 units of Xtant Medical Inc stock worth over $2,039,419 and over the last 7 years he sold XTNT stock worth over $0. In addition, he makes $0 as Director at Xtant Medical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rizzo XTNT stock SEC Form 4 insiders trading

Matthew has made over 1 trades of the Xtant Medical Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 945,819 units of XTNT stock worth $6,809,897 on 14 February 2018.

The largest trade he's ever made was buying 945,819 units of Xtant Medical Inc stock on 14 February 2018 worth over $6,809,897. On average, Matthew trades about 94,582 units every 0 days since 2018. As of 14 February 2018 he still owns at least 3,316,128 units of Xtant Medical Inc stock.

You can see the complete history of Mr. Rizzo stock trades at the bottom of the page.

Matthew Rizzo biography

Matthew S. Rizzo serves as Director of the Company. He is a Partner with OrbiMed Advisors LLC, having joined the firm in April 2010, and is focused on healthcare royalty and structured finance investments. Previously, Mr. Rizzo was at Ikaria Holdings as a Senior Director in business development for pharmaceutical licensing and acquisitions. Prior to Ikaria, Mr. Rizzo was a Vice President at Fortress Investment Group, focused on healthcare investments in the Drawbridge Special Opportunities Funds. Prior to Fortress, he was at GlaxoSmithKline where he worked in business and commercial analysis. Mr. Rizzo received his M.B.A. from Duke University and his B.S. from the State University of New York at Buffalo. Mr. Rizzo brings valuable experience in the life science industry and finance experience to the Board.

What's Matthew Rizzo's mailing address?

Matthew's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.

Insiders trading at Xtant Medical Inc

Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed, and Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.

What does Xtant Medical Inc do?

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Complete history of Mr. Rizzo stock trades at Xtant Medical Inc

Xtant Medical Inc executives and stock owners

Xtant Medical Inc executives and other stock owners filed with the SEC include:

• Sean E. Browne,
  Pres, CEO & Director
• Kevin D. Brandt,
  Sr. VP & Chief Commercial Officer
• Darrel Holmes,
  Chief Operating Officer
• Gregory Juda,
  Chief Scientific Officer
• Rich Cockrell,
  IR Contact Officer
• Matthew Rizzo,
  Director
• Jeffrey Peters,
  Director
• Robert McNamara,
  Director
• Michael Eggenberg,
  Director
• John Bakewell,
  Director
• Kevin Brandt,
  Senior Vice President, Chief Commercial Officer
• Greg Jensen,
  Chief Financial Officer, Vice President - Finance
• Sean Browne,
  President, Chief Executive Officer, Director
• Kevin M. O'Dare,
  VP of Sales - Eastern US
• Catherine Lundy,
  VP of HR
• Scott Neils,
  Interim CFO & Controller
• Scott C Neils,
  Chief Financial Officer
• Jonn R. Beeson,
  Director
• Eric Bernard Timko,
  Director
• Kent L Swanson,
  Director
• John Arthur Deedrick,
  Director
• David Louis Kirschman,
  EVP & Chief Scientific Officer
• Daniel S Goldberger,
  Chief Executive Officer
• Rudy A Mazzocchi,
  Director
• Jon M. Wickwire,
  
• David Goodman,
  
• Paul Buckman,
  Director
• Michael A Lopach,
  Director
• Advisors Llc Orbimed,
  Director
• Kathie J. Lenzen,
  Chief Financial Officer
• Carl O'connell,
  Chief Executive Officer
• Michael Mainelli,
  Interim CEO
• Ronald G. Berlin,
  VP & Chief Operations Officer
• Advisors Llc Orbimed Rof Ii...,
  
• Lori D Mitchell Keller,
  Director
• Mark A. Schallenberger,
  Chief Operations Officer
• Stavros G. Vizirgianakis,
  Director